RxDoctor Payments Data

Faramarz Samie, MD

MOHS-Micrographic Surgery · New York, NYNPI 1982646782

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $5,280 of the $5,294 with a category attached, or 99.7%. Sanofi accounts for 99.7% of it on its own, with 1 other manufacturer making up the rest. 2021 is the largest year on record at $2,816, more than ten times the $14 reported in 2019.

$5,294in general payments, 2019–2025

Across 3 payments — averaging $1764.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$5K
  • Merck$14
$29,314in research payments, 2019–2025

Across 13 payments — averaging $2254.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$29K

What the payments were for

  • Consulting fees$5,280100%
  • Food & beverage$140%

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sanofi2$5,280
Merck1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,294 in reported general payments places this provider in the 75th percentile of 75 mohs-micrographic surgery providers in New York.

See all mohs-micrographic surgery providers in New York

Medicare billing

Part B allowed, 2024
$631,831
Medicare patients
512
Services billed
2,034

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Fluorouracil31$1,830
Imiquimod12$233
Triamcinolone Acetonide12$49

Paid to pharmacies, not to this prescriber.

Other mohs-micrographic surgery in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →